ATE502647T1 - Zubereitungen enthaltend sincalide - Google Patents

Zubereitungen enthaltend sincalide

Info

Publication number: ATE502647T1
Authority: AT; Austria
Prior art keywords: sincalide; preparations containing; methods; formulations; sincalide formulations
Prior art date: 2002-08-16

Application number

AT03818433T

Other languages

English (en)

Inventor

Edmund Metcalfe

Jo Anna Monteferrante

Margaret Newborn

Irene Ropiak

Ernst Schramm

Gregory White

Jules Zodda

Original Assignee

Bracco Suisse Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-08-16

Filing date

2003-08-15

Publication date

2011-04-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31714996&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE502647(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-08-15 Application filed by Bracco Suisse Sa filed Critical Bracco Suisse Sa

2011-04-15 Application granted granted Critical

2011-04-15 Publication of ATE502647T1 publication Critical patent/ATE502647T1/de

Links

108010087230 Sincalide Proteins 0.000 title abstract 5
IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 title abstract 5
229960002959 sincalide Drugs 0.000 title abstract 5
238000002360 preparation method Methods 0.000 title 1
238000009472 formulation Methods 0.000 abstract 3
239000000203 mixture Substances 0.000 abstract 3
238000000034 method Methods 0.000 abstract 2
239000004067 bulking agent Substances 0.000 abstract 1
239000002738 chelating agent Substances 0.000 abstract 1
210000000232 gallbladder Anatomy 0.000 abstract 1
239000003381 stabilizer Substances 0.000 abstract 1
239000004094 surface-active agent Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2207—Gastrins; Cholecystokinins [CCK]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oil, Petroleum & Natural Gas (AREA)
Gastroenterology & Hepatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Inorganic Chemistry (AREA)
Physics & Mathematics (AREA)
Optics & Photonics (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT03818433T 2002-08-16 2003-08-15 Zubereitungen enthaltend sincalide ATE502647T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10/222,540 US6803046B2 (en)	2002-08-16	2002-08-16	Sincalide formulations
PCT/IB2003/006513 WO2005027954A2 (en)	2002-08-16	2003-08-15	Sincalide formulations

Publications (1)

Publication Number	Publication Date
ATE502647T1 true ATE502647T1 (de)	2011-04-15

Family

ID=31714996

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03818433T ATE502647T1 (de)	2002-08-16	2003-08-15	Zubereitungen enthaltend sincalide

Country Status (9)

Country	Link
US (13)	US6803046B2 (de)
EP (1)	EP1631305B1 (de)
JP (1)	JP4751993B2 (de)
CN (1)	CN100374154C (de)
AT (1)	ATE502647T1 (de)
AU (1)	AU2003304382B2 (de)
CA (1)	CA2503982C (de)
DE (1)	DE60336509D1 (de)
WO (1)	WO2005027954A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1703233A (zh) *	2002-07-12	2005-11-30	米德列斯公司	防止蛋白氧化降解的方法和组合物
US6803046B2 (en) *	2002-08-16	2004-10-12	Bracco International B.V.	Sincalide formulations
US20050256097A1 (en) *	2004-05-11	2005-11-17	Kosan Biosciences, Inc.	Pharmaceutical solution formulations containing 17-AAG
US20070243264A1 (en) *	2006-04-18	2007-10-18	Aram Garabedian	Thickened Dilute Hypochlorite
US7923425B2 (en) *	2006-08-21	2011-04-12	Henkel Ag & Co. Kgaa	Low-foaming, acidic low-temperature cleaner and process for cleaning surfaces
EP2471507B1 (de)	2006-09-29	2017-03-01	Johnson & Johnson Vision Care, Inc.	Ophthalmische Vorrichtungen zur Behandlung von Augenallergien
WO2008042408A2 (en) *	2006-10-03	2008-04-10	Wyeth	Lyophilization methods and apparatuses
US8389014B2 (en) *	2006-12-22	2013-03-05	Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.	Gel useful for the delivery of ophthalmic drugs
WO2009008595A1 (en)	2007-07-10	2009-01-15	Medy-Tox, Inc.	Pharmaceutical liquid composition of botulinum toxin with improved stability
US9801818B2 (en) *	2007-12-31	2017-10-31	Samyang Biopharmaceuticals Corporation	Method for stabilizing amphiphilic block copolymer micelle composition containing poorly water-soluble drug
EP2236520A1 (de) *	2009-03-31	2010-10-06	Leukocare Ag	Stabilisierungszusammensetzung für immobilisierte Biomoleküle
CN103027890B (zh) *	2011-09-29	2014-06-18	天津市汉康医药生物技术有限公司	供注射用的布洛芬药物组合物
HRP20161703T1 (hr)	2012-11-20	2017-03-10	Fresenius Kabi Usa, Llc	Formulacije kaspofungin acetata
ES2586945T3 (es)	2014-03-31	2016-10-19	Vasopharm Gmbh	Composiciones farmacéuticas sólidas que comprenden derivados de biopterina y usos de dichas composiciones
CN104761645A (zh) *	2015-04-30	2015-07-08	山东禹王制药有限公司	α干扰素融合蛋白制剂及应用
WO2017059092A1 (en) *	2015-09-30	2017-04-06	Duke University	Ascorbate formulations and methods of use as contrast agents
US20180360917A1 (en) *	2017-06-15	2018-12-20	Apicore Llc	Sincalide formulations and methods of use
US11110063B2 (en)	2017-08-25	2021-09-07	MAIA Pharmaceuticals, Inc.	Storage stable sincalide formulations
MY202872A (en) *	2017-11-20	2024-05-28	Just Evotec Biologics Inc	Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
CA3112060A1 (en) *	2018-10-12	2020-04-16	Advanced Accelerator Applications International Sa	Pharmaceutical composition comprising a radiolabeled gprp antagonist and a surfactant
US11809191B2 (en)	2020-09-29	2023-11-07	Topcon Positioning Systems, Inc.	Maneuvering system for autonomous wheeled robot for optimally reaching starting point
JP2023119488A (ja) *	2022-02-16	2023-08-28	ニプロ株式会社	スガマデクス含有の液体製剤

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3723406A (en)	1969-12-23	1973-03-27	Squibb & Sons Inc	Novel peptides having cholecystokinin activity and intermediates therefor
US3937819A (en) *	1974-07-22	1976-02-10	E. R. Squibb & Sons, Inc.	Method of stabilizing an injectable composition of a cholecystokinin active octapeptide
IT1204430B (it) *	1986-01-10	1989-03-01	Alfio Bertolini	Composizioni farmaceutiche comprendenti peptidi del gruppo colecistochinina-cerulina per il trattamento terapeutico degli stati di shock e dell'insufficienza respiratoria e cardiocircolatoria
US5011678A (en) *	1989-02-01	1991-04-30	California Biotechnology Inc.	Composition and method for administration of pharmaceutically active substances
JPH03505334A (ja) *	1989-04-11	1991-11-21	イミユノバイオロジー・リサーチ・インスチチユート・インコーポレーテツド	凍結乾燥されたペプチド製剤
IN172208B (de)	1990-04-02	1993-05-01	Sint Sa
US5556610A (en) *	1992-01-24	1996-09-17	Bracco Research S.A.	Gas mixtures useful as ultrasound contrast media, contrast agents containing the media and method
TW274552B (de) *	1992-05-26	1996-04-21	Hoechst Ag
US5373613A (en)	1992-10-23	1994-12-20	Young Engineering, Inc.	Tenter frame with pinned roll transfer means
JPH06273415A (ja) *	1993-03-18	1994-09-30	Unitika Ltd	コレシストキニンの測定用試薬及び測定方法
GB9407386D0 (en)	1994-04-14	1994-06-08	Smithkline Beecham Plc	Pharmaceutical formulation
FR2719479B1 (fr) *	1994-05-04	1996-07-26	Sanofi Elf	Formulation stable lyophilisée comprenant une protéine: kit de dosage.
US5676950A (en) *	1994-10-28	1997-10-14	University Of Florida	Enterically administered recombinant poxvirus vaccines
US5833948A (en)	1995-06-15	1998-11-10	Bracco Research S.A.	Blood-pool imaging composition comprising micelles containing a lipophilic chelating agent and a non-ionic surfactant
DE19645250A1 (de)	1996-11-02	1998-05-07	Merck Patent Gmbh	Stabile wäßrige Formulierung von 3-(N-Butylacetamino)-propionsäureethylester
CH692322A5 (it)	1997-05-26	2002-05-15	Westy Ag	Formulazione iniettabile limpida di Propofol.
ES2252993T3 (es) *	1998-12-09	2006-05-16	Chiron Corporation	Administracion de agentes neurotroficos al sistema nervioso central.
JP2000247903A (ja) *	1999-03-01	2000-09-12	Chugai Pharmaceut Co Ltd	長期安定化製剤
SE9901578D0 (sv) *	1999-05-03	1999-05-03	Karolinska Innovations Ab	New use of substance in PNS
US6440414B1 (en) *	1999-10-01	2002-08-27	Amgen Inc.	Pharmaceutical compositions of fibrinolytic agent
US6579521B2 (en) *	2000-10-20	2003-06-17	Chiron Corporation	Methods of therapy for HIV infection
US6803046B2 (en) *	2002-08-16	2004-10-12	Bracco International B.V.	Sincalide formulations

2002
- 2002-08-16 US US10/222,540 patent/US6803046B2/en not_active Expired - Lifetime
2003
- 2003-08-15 CA CA2503982A patent/CA2503982C/en not_active Expired - Lifetime
- 2003-08-15 DE DE60336509T patent/DE60336509D1/de not_active Expired - Lifetime
- 2003-08-15 WO PCT/IB2003/006513 patent/WO2005027954A2/en not_active Ceased
- 2003-08-15 AU AU2003304382A patent/AU2003304382B2/en not_active Expired
- 2003-08-15 CN CNB038241374A patent/CN100374154C/zh not_active Expired - Lifetime
- 2003-08-15 EP EP03818433A patent/EP1631305B1/de not_active Expired - Lifetime
- 2003-08-15 AT AT03818433T patent/ATE502647T1/de not_active IP Right Cessation
- 2003-08-15 JP JP2005509018A patent/JP4751993B2/ja not_active Expired - Lifetime
2004
- 2004-08-19 US US10/921,732 patent/US20050020502A1/en not_active Abandoned
2009
- 2009-10-28 US US12/607,337 patent/US20100047175A1/en not_active Abandoned
2011
- 2011-12-02 US US13/309,848 patent/US20120128581A1/en not_active Abandoned
2013
- 2013-10-28 US US14/064,379 patent/US20140065071A1/en not_active Abandoned
2014
- 2014-10-02 US US14/504,498 patent/US20150017097A1/en not_active Abandoned
2015
- 2015-04-27 US US14/696,658 patent/US20150224166A1/en not_active Abandoned
2016
- 2016-09-30 US US15/281,489 patent/US20170014470A1/en not_active Abandoned
2017
- 2017-05-05 US US15/587,471 patent/US20170281719A1/en not_active Abandoned
- 2017-11-08 US US15/807,555 patent/US20180064781A1/en not_active Abandoned
2019
- 2019-10-01 US US16/589,230 patent/US20200030406A1/en not_active Abandoned
2020
- 2020-04-27 US US16/858,815 patent/US20200254052A1/en not_active Abandoned
- 2020-10-01 US US17/060,191 patent/US20210093689A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20170014470A1 (en)	2017-01-19
US6803046B2 (en)	2004-10-12
US20140065071A1 (en)	2014-03-06
AU2003304382B2 (en)	2008-11-06
US20200254052A1 (en)	2020-08-13
JP4751993B2 (ja)	2011-08-17
AU2003304382A1 (en)	2005-04-28
DE60336509D1 (de)	2011-05-05
US20210093689A1 (en)	2021-04-01
CN100374154C (zh)	2008-03-12
WO2005027954A3 (en)	2005-10-20
US20150224166A1 (en)	2015-08-13
US20170281719A1 (en)	2017-10-05
US20050020502A1 (en)	2005-01-27
US20040033243A1 (en)	2004-02-19
CA2503982A1 (en)	2005-03-31
US20200030406A1 (en)	2020-01-30
US20180064781A1 (en)	2018-03-08
WO2005027954A2 (en)	2005-03-31
JP2006515321A (ja)	2006-05-25
US20100047175A1 (en)	2010-02-25
US20120128581A1 (en)	2012-05-24
CA2503982C (en)	2011-09-27
US20150017097A1 (en)	2015-01-15
EP1631305A2 (de)	2006-03-08
CN1756557A (zh)	2006-04-05
EP1631305B1 (de)	2011-03-23

Legal Events

Date	Code	Title	Description
2011-09-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60336509D1 (de)	2011-05-05	Zubereitungen enthaltend sincalide
IL138476A0 (en)	2001-10-31	Method for treating pharmaceutical compositions by special use of anti-oxidant
IS6950A (is)	2003-09-12	Samsetning epóþílonhliðstæðna og efnameðferðarlyfja til meðhöndlunar frumufjölgunarsjúkdóma
AU2002360488A8 (en)	2003-09-29	Methods and devices for detection and therapy of atheromatous plaque
DK1718677T3 (da)	2012-07-09	Monovalente antistoffragmenter egnede som terapeutiske midler
MXPA03011006A (es)	2004-02-27	Compuestos de cicloalquil urea benzo-fusionados 1,4-disustituidos.
BR0315157A (pt)	2005-08-09	Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste
ATE289640T1 (de)	2005-03-15	Amidofunktionelle aminopolydiorganosiloxane
NO20042964L (no)	2004-09-07	Spiroazasykliske forbindelser som monoaminreseptormodulatorer
EP1404356A4 (de)	2005-04-06	Cd10-aktivierte prodrug-verbindungen
TR200003036T2 (tr)	2001-01-22	12,13-Modifiye edilmiş epotilon türevleri
ATE433973T1 (de)	2009-07-15	Azolylaminoazine als inhibitoren von proteinkinasen
ATE556706T1 (de)	2012-05-15	Fettalkohol-arzneimittel-konjugate
WO2001044247A3 (en)	2002-01-03	Agents and methods for the treatment of proliferative diseases
BR0011225A (pt)	2002-03-19	Agente para tratar de olhos secos, seu método e uso
NO20044530L (no)	2004-10-21	Fremgangsmate for behandling av kognitive forstyrrelser
ATE443044T1 (de)	2009-10-15	Tace inhibitoren
ITRM20000266A0 (it)	2000-05-17	Procedimento migliorato per la preparazione di (e,z) 3-(2-amminoetossimmino)-androstano-6, 17-dione e di suoi analoghi.
TW200512009A (en)	2005-04-01	Hair treatment compositions
BR0111785A (pt)	2003-05-20	Composições e métodos para tratamento de candidìase
MXPA03010737A (es)	2004-03-02	Aril-8-azabiciclo(3.2.1) octanos para tratamiento de depresion.
SE0100374D0 (sv)	2001-02-07	Novel compositions of potassium channel openers and protein kinase c inhibitors and use thereof
WO2001044235A3 (en)	2002-01-17	Agents and methods for the treatment of proliferative diseases
ATE323493T1 (de)	2006-05-15	Gesteuerte freisetzung von antidepressiva
PT1276722E (pt)	2006-07-31	Inibidores de naftamidina-uroquinase